1. Non-alcoholic Fatty liver Disease in Patients with Psoriasis - Therapeutic Implications
- Author
-
Anna B. Witkowska, Elżbieta Halina Kłujszo, Beata Kręcisz, and Piotr Parcheta
- Subjects
medicine.medical_specialty ,biologic agents ,Dermatology ,Disease ,Type 2 diabetes ,digestive system ,Gastroenterology ,methotrexate ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Insulin resistance ,Psoriasis ,Internal medicine ,medicine ,Immunology and Allergy ,Review Paper ,business.industry ,Fatty liver ,nutritional and metabolic diseases ,psoriasis ,medicine.disease ,RC31-1245 ,Obesity ,digestive system diseases ,RL1-803 ,Metabolic syndrome ,liver disease ,business - Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology in the western countries. Psoriatic patients are at higher risk of having NAFLD, and at higher risk of experiencing a more severe form of the disease with poorer outcomes. The components of the metabolic syndrome - obesity, lipid abnormalities, hypertension, and type 2 diabetes - significantly correlate with NAFLD progression. The inflammatory state present in psoriasis plays a significant role in development of NAFLD and the metabolic syndrome. All patients with psoriasis and insulin resistance and risk factors for metabolic syndrome should also been screened for NAFLD, and planning of the treatment options should always take into consideration the possible risks related to the liver, especially in patients with NAFLD.
- Published
- 2020
- Full Text
- View/download PDF